<DOC>
	<DOCNO>NCT01856426</DOCNO>
	<brief_summary>The purpose study , ass whether EDP239 reduce HCV viral load HCV gentotype-1 chronically infected subject evaluate safety profile EDP239 .</brief_summary>
	<brief_title>Proof Concept Study Safety Efficacy EDP239 Hepatitis C Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subjects must chronic genotype1 hepatitis C virus infection plasma HCVRNA ≥ 105 IU/mL time screen . Subjects must chronic HCV infection determine follow : antiHCV ( + ) least 6 month per subject history medical record antiHCV test , viral load , genotype &gt; 6 month ago In set recent positive antiHCV test ( &lt; 6 month ) , liver biopsy demonstrate chronicity Subjects must IL28b genotype `` CC '' Subjects must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 36 kg/m2 . BMI = Body weight ( kg ) / [ Height ( ) ] 2 Use investigational drug time enrollment , within 5 halflives enrollment , within 30 day ( small molecule ) whichever longer ; longer require local regulation . Previous treatment , include use investigational agent , treatment HCV infection . Women child bear potential . Subjects IL28b genotype `` CT TT '' . ALT γGT , AST must 5 x upper limit normal ( ULN ) . Serum bilirubin must exceed ULN . The PT ( INR ) must within normal limit . If necessary , laboratory testing may repeat one occasion ( soon possible ) prior randomization , rule laboratory error . Use drug inhibit induce CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis C infect subject</keyword>
</DOC>